

Current Status of Infectious Diseases Education at United States Colleges of Pharmacy

Jonathan C. Cho¹, Conan MacDougall², Lauren R. Biehle³, Navaneeth Narayanan⁴, Meghan N. Jeffres⁵

¹The University of Texas at Tyler College of Pharmacy; ²University of California San Francisco School of Pharmacy; ³University of Wyoming School of Pharmacy; ⁴Rutgers University Ernest Mario School of Pharmacy; ⁵University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences



BACKGROUND

The Accreditation Council for Pharmacy
Education (ACPE) requires infectious diseases
(ID) pharmacotherapy be integrated in Doctor
of Pharmacy (PharmD) curricula. However,
guidance on the specific topics and extent of
coverage that should be provided are lacking.
Understanding best practices in relation to ID
education can aid faculty to design curricula
that will better prepare pharmacists to optimize
patients' antimicrobial needs.

OBJECTIVES

To describe content and pedagogical strategies employed for didactic ID education at United States colleges of pharmacy.

METHODS

A 23-question cross-sectional electronic survey was distributed via e-mail to ID course coordinators at 137 pharmacy schools. The survey was created using investigators' input and the 2016 American College of Clinical Pharmacy (ACCP) Pharmacotherapy Didactic Curriculum Toolkit, and pilot tested among steering committee members of the Infectious Diseases Educator Network (ID-EN). Survey responses were collected through Qualtrics (Qualtrics, Inc. Provo, UT) and analyzed using SPSS Statistics, version 24 (IBM, Armonk, NY, USA). Free text responses were reviewed and characterized by the authors.

RESULTS

Table 1. Pharmacy School Demographics.

| Demographics | N=106 (%) |
|-------------------------------|-----------|
| Accredited by ACPE | 97 (91.5) |
| Private | 56 (52.8) |
| Age of school | , , |
| ≤ 10 years | 32 (30.2) |
| > 10 years | 74 (69.8) |
| Class size | |
| ≤100 students | 54 (50.9) |
| 101-200 students | 41 (38.7) |
| > 200 students | 11 (10.4) |
| Length of curriculum | |
| 3 years | 11 (10.4) |
| 4 years | 95 (89.6) |
| Curricular format | |
| Semesters | 69 (65.1) |
| Blocks | 24 (22.6) |
| Quarters | 13 (12.3) |
| Curriculum years ID is taught | |
| First | 20 (18.8) |
| Second | 57 (53.8) |
| Third | 75 (70.8) |
| | |

Figure 1. Percent Dedicated Fundamentals




Figure 2. Percentage of Lecture vs. Active Learning Used in ID Curriculum.





Figure 3. Curricular Coverage of ACCP Pharmacotherapy Didactic Curriculum Toolkit ID Topics.



DISCUSSION

One-hundred and six (77%) faculty responded to the survey. Most pharmacy schools dedicated 40-80 hours to their ID curriculum, teaching primarily through traditional lecture formats. All toolkit tier one topics were covered in greater than 94% of schools but the percentage of schools teaching tiers two and three topics varied greatly.

CONCLUSION

Although pharmacy schools taught most tier one ID topics, increased use of active learning modalities may enhance ID education.

Additionally, allocation of curricular time dedicated to fundamentals and disease states should be evaluated.

REFERENCES

- . Accreditation Council for Pharmacy Education. Accreditation standards and key elements for the professional program in pharmacy leading to the doctor of pharmacy degree Standards 2016. https://www.acpe-accredit.org/pdf/Standards2016FINAL.pdf.
- 2. Schwinghammer TL, Crannage AJ, Boyce EG, et al. The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit. *Pharmacotherapy*. Nov 2016;36(11):e189-e94.
- Justo JA, Gauthier TP, Scheetz MH, et al. Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. Clin Infect Dis.. 2014 Oct 15;59 Suppl 3:S162-9.

DISCLOSURES

- <u>Financial disclosures:</u> Associate Dean of Research Educational Research Seed Grant Program at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provided grant funding for this project.
- <u>Potential conflicts of interest:</u> JCC serves on the speaks bureau for Allergan. CM served as a consultant for Allergan and Shionogi and has received grant support from Merck.